United Therapeutics (NASDAQ:UTHR) Stock Rated “Sell” in New Coverage at The Goldman Sachs Group

The Goldman Sachs Group initiated coverage on shares of United Therapeutics (NASDAQ:UTHR) in a note issued to investors on Thursday, Marketbeat.com reports. The firm set a “sell” rating and a $321.00 price target on the biotechnology company’s stock. The Goldman Sachs Group’s target price suggests a potential downside of 32.49% from the stock’s current price.

UTHR has been the topic of a number of other reports. Royal Bank Of Canada cut their target price on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. Weiss Ratings lowered shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, August 27th. Bank of America reduced their price objective on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research note on Friday, July 10th. JPMorgan Chase & Co. boosted their target price on United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. Finally, Morgan Stanley set a $515.00 price objective on United Therapeutics in a report on Thursday, August 6th. Eleven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $621.00.

United Therapeutics Stock Performance

Shares of UTHR traded up $3.24 during mid-day trading on Thursday, hitting $475.45. 472,424 shares of the company’s stock were exchanged, compared to its average volume of 516,937. The company has a market cap of $20.39 billion, a price-to-earnings ratio of 17.01, a P/E/G ratio of 2.49 and a beta of 0.56. United Therapeutics has a fifty-two week low of $409.07 and a fifty-two week high of $609.35. The stock’s 50-day moving average is $512.06 and its 200-day moving average is $540.50.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The firm had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. During the same quarter in the previous year, the business posted $6.41 earnings per share. The business’s quarterly revenue was down 1.9% compared to the same quarter last year. As a group, equities research analysts anticipate that United Therapeutics will post 26.21 EPS for the current year.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $545.80, for a total transaction of $5,185,100.00. Following the completion of the sale, the chief executive officer owned 40,513 shares of the company’s stock, valued at approximately $22,111,995.40. The trade was a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last quarter, insiders have sold 355,553 shares of company stock valued at $184,183,266. 8.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On United Therapeutics

Several hedge funds have recently modified their holdings of UTHR. BlackRock Inc. acquired a new position in United Therapeutics during the second quarter worth $2,868,735,000. Jupiter Topco LLC acquired a new position in shares of United Therapeutics during the second quarter worth approximately $450,140,000. Norges Bank bought a new stake in shares of United Therapeutics in the fourth quarter valued at approximately $293,418,000. Bank of New York Mellon Corp bought a new position in United Therapeutics during the second quarter worth $159,522,000. Finally, Caisse de depot et placement du Quebec bought a new position in United Therapeutics during the second quarter worth $154,304,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: United Therapeutics is using the remainder of its $2 billion share-repurchase authorization through an accelerated share repurchase. A lower share count could support earnings per share and provide a potential source of demand for the stock.
• Neutral Sentiment: The company’s latest quarterly earnings exceeded expectations, with EPS of $7.27 versus the $6.86 consensus estimate. However, revenue of $783.3 million missed forecasts and declined 1.9% year over year, leaving investors focused on whether newer products can offset pressure on the established business.
• Negative Sentiment: Goldman Sachs initiated coverage with a Sell rating and a $321 price target, arguing that UTHR’s valuation is too high relative to its long-term growth prospects. The call represents a substantial downside risk compared with recent trading levels. United Therapeutics, Sagimet drop after Goldman issues Sell ratings
• Negative Sentiment: The Goldman analysis cited a shrinking core business, reimbursement and payer risks, potential generic competition, and a challenging launch outlook for Tyvaso and Jenraldi. Questions about real-world adoption of Jenraldi and broader coverage for nebulized Tyvaso could limit future revenue growth. United Therapeutics downgraded to Sell
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares for approximately $4.7 million, reducing her holdings by 2.84%. The transaction may weigh on sentiment, particularly alongside reports of substantial insider selling without reported purchases, although it could reflect routine personal or tax-related planning. SEC insider transaction filing

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company’s products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics’ PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.